A Dose Escalating Phase I Study, Double-blind, Randomized, Placebo-controlled for Examining the Safety and Tolerability to a Prophylactic HIV-1 Vaccine Called MYM-V101, Administered i.m. in Combination With i.n. Administrations to Healthy Female Subjects.

This study is designed to investigate the safety and efficacy of a newly developed vaccine against HIV-1 in female healthy subjects. Safety will be assessed by local and systemic adverse reactions, investigations of blood and urine, and physical exam including vital sign measurements. Efficacy will be assessed in blood, and in vaginal and rectal mucosal samples.

开始日期2009-11-01

申办/合作机构

Mymetics Corp.

[+7]

100 项与 Second generation virosome-based HIV vaccine(Mymetics Corp.) 相关的临床结果

登录后查看更多信息

100 项与 Second generation virosome-based HIV vaccine(Mymetics Corp.) 相关的转化医学

登录后查看更多信息

100 项与 Second generation virosome-based HIV vaccine(Mymetics Corp.) 相关的专利（医药）

登录后查看更多信息

项与 Second generation virosome-based HIV vaccine(Mymetics Corp.) 相关的文献（医药）

2019-04-01·Cell Reports1区 · 生物学

HIV-1 Envelope Recognition by Polyreactive and Cross-Reactive Intestinal B Cells

1区 · 生物学

ArticleOA

作者: Laurent Hocqueloux ; Hugo Mouquet ; Tim Rollenske ; Laurent Lefrou ; Ayrin Kök ; Jordan D. Dimitrov ; Thierry Prazuck ; Julie Prigent ; Florence Guivel-Benhassine ; Cyril Planchais ; Olivier Schwartz ; Timothée Bruel ; Thierry Hieu ; Hedda Wardemann ; Valérie Lorin ; Alexia Kanyavuz

Mucosal immune responses to HIV-1 involve the recognition of the viral envelope glycoprotein (gp)160 by tissue-resident B cells and subsequent secretion of antibodies. To characterize the B cells "sensing" HIV-1 in the gut of infected individuals, we probed monoclonal antibodies produced from single intestinal B cells binding to recombinant gp140 trimers. A large fraction of mucosal B cell antibodies were polyreactive and showed only low affinity to HIV-1 envelope glycoproteins, particularly the gp41 moiety. A few high-affinity gp140 antibodies were isolated but lacked neutralizing, potent ADCC, and transcytosis-blocking capacities. Instead, they displayed cross-reactivity with defined self-antigens. Specifically, intestinal HIV-1 gp41 antibodies targeting the heptad repeat 2 region (HR2) cluster II cross-reacted with the p38α mitogen-activated protein kinase 14 (MAPK14). Hence, physiologic polyreactivity of intestinal B cells and molecular mimicry-based self-reactivity of HIV-1 antibodies are two independent phenomena, possibly diverting and/or impairing mucosal humoral immunity to HIV-1.

2019-04-01·Computational Biology and Chemistry4区 · 生物学

Gp41 inhibitory activity prediction of theaflavin derivatives using ligand/structure-based virtual screening approaches

4区 · 生物学

Article

作者: Fassihi, Afshin ; Mostashari-Rad, Tahereh ; Saghaei, Lotfollah

Gp41 and its conserved hydrophobic groove on the NHR region is one of the attractive targets in the design of HIV-1 entry inhibitory agents. This hydrophobic pocket is very critical for the progression of HIV and host cell fusion. In this study different ligand-based (structure similarity search) and structure-based (molecular docking and molecular dynamic simulation) methods were performed in a virtual screening procedure to select the best compounds with the most probable HIV-1 gp41 inhibitory activities. In silico pharmacokinetics and ADMET (absorption, distribution, metabolism, excretion and toxicity) properties filtration also was considered to choose the compounds with best drug-like properties. The results of molecular docking and molecular dynamic simulations of the final selected compounds showed suitable stabilities of their complexes with gp41. The final selected hits could have better pharmacokinetics properties than the template compound, theaflavin digallate (TF₃), a naturally-originated potent gp41 inhibitor.

2018-10-17·Bioconjugate Chemistry2区 · 化学

Selective Uptake Into Drug Resistant Mammalian Cancer by Cell Penetrating Peptide-Mediated Delivery

2区 · 化学

Article

作者: Laufersky, Geoffry ; Morgan, Thomas J. ; Levenson, Cathy W. ; Strouse, Geoffrey F. ; Carnevale, Kate J. F. ; Foley, Megan E. ; Zorio, Diego A. R. ; Muroski, Megan E. ; Vakil, Parth N. ; Kenworthy, Rachael

Research over the past decade has identified several of the key limiting features of multidrug resistance (MDR) in cancer therapy applications, such as evolving glycoprotein receptors at the surface of the cell that limit therapeutic uptake, metabolic changes that lead to protection from multidrug resistant mediators which enhance degradation or efflux of therapeutics, and difficulty ensuring retention of intact and functional drugs once endocytosed. Nanoparticles have been demonstrated to be effective delivery vehicles for a plethora of therapeutic agents, and in the case of nucleic acid based agents, they provide protective advantages. Functionalizing cell penetrating peptides, also known as protein transduction domains, onto the surface of fluorescent quantum dots creates a labeled delivery package to investigate the nuances and difficulties of drug transport in MDR cancer cells for potential future clinical applications of diverse nanoparticle-based therapeutic delivery strategies. In this study, eight distinct cell penetrating peptides were used (CAAKA, HSV1-VP22, HIV-TAT, HIV-gp41, Ku-70, hCT(9-32), integrin-β3, and K-FGF) to examine the different cellular uptake profiles in cancer versus drug resistant melanoma (A375 & A375-R), mesothelioma (MSTO & MSTO-R), and glioma (rat 9L and 9L-R, and human U87 & LN18) cell lines. The results of this study demonstrate that cell penetrating peptide uptake varies with drug resistance status and cell type, likely due to changes in cell surface markers. This study provides insight into developing functional nanoplatform delivery systems in drug resistant cancer models.

100 项与 Second generation virosome-based HIV vaccine(Mymetics Corp.) 相关的药物交易

登录后查看更多信息